|
◇Lemon Healthcare Shrugs Off "Sewol Commemoration Text" Blunder to Hit Upper Limit on Turnaround Hopes
Digital healthcare data platform provider Lemon Healthcare closed at its daily upper limit of 6,990 KRW(29.93%). The company recently faced fierce backlash when it was revealed that its patient-facing mobile apps at major university hospitals had left a sample date input string matching the day of the Sewol ferry disaster (20140416) unverified for years. Although CEO Hong Byung-jin issued a formal apology to the victims' families and the public, investor focus quickly shifted to the company's financial turnaround prospects.Market participants note that Lemon Healthcare stands out because it actually generates profits despite being listed via the technology exception track. The company posted a revenue of 15.9 billion KRW and an operating loss of 600 million KRW last year. For this year, it projects an operating profit of 6.5 billion KRW on a revenue of 24.1 billion KRW, marking its first profitable year since inception. It has set a further blueprint for 2027, targeting 29.6 billion KRW in revenue and 11.3 billion KRW in operating profit.The underlying technology remains solid. Lemon Healthcare secured grades of A and A from NICE Information Service and Korea Ratings Data during its technology assessment. Its "Lemon Digital Bridge" (LDB) platform links closed electronic medical record (EMR) systems at large hospitals, powering real-time medical data ecosystems like the simplified indemnity insurance claim service "Silson24." The system is running stably across more than 130 major hospitals, including Seoul National University Hospital and Severance Hospital. The company plans to use the capital raised from its listing to invest in AI training data infrastructure and expand its cloud capacity to widen the gap with competitors.
|
◇Samchungdang Pharm Soars on FDA Pre-ANDA Response, but Regulatory Hurdles Just
BeginningSamchungdang Pharm, which previously saw its stock plunge after being designated an unfaithful disclosure corporation and facing scrutiny over its contract structure, rebounded sharply on easing regulatory uncertainties. The stock jumped 29.82% to finish at 239,000 KRW. The surge came after the company announced it received a Pre-ANDA (Abbreviated New Drug Application) response from the US Food and Drug Administration (FDA) regarding its development strategy for an oral semaglutide generic.Securing regulatory guidelines for an oral version of a glucagon-like peptide-1 (GLP-1) generic is a clear catalyst given the booming global obesity and diabetes market. A representative for Samchungdang Pharm stated, "The FDA response clarifies the regulatory path for our oral generic. Combined with our push to sign advance supply contracts in the US and European markets, this is an opportunity to prove the global value of our proprietary oral drug delivery technology, S-PASS."However, market experts warn investors not to mistake a Pre-ANDA response for final approval. A Pre-ANDA meeting simply allows a generic developer to review its filing strategy with the FDA before making a formal submission. To secure actual marketing clearance, the company must still clear the formal ANDA review process, which involves rigorous testing of bioequivalence, product quality, and Good Manufacturing Practice (GMP) facility inspections. Given that Samchungdang was penalized by the Korea Exchange for omitting overseas performance data for its Eylea biosimilar, potential regulatory pushbacks like a Complete Response Letter (CRL) cannot be ruled out during the final filing stages."Because the response document contains confidential details regarding our S-PASS platform and commercial strategy, we cannot disclose the full text," the company official added. "Publishing isolated sentences could distort the true context.“
|
◇ROKIT Healthcare Gains on 8x Boost to US Target Market, but Hair Regrowth Data Stays Hidden
Organ regeneration platform developer ROKIT Healthcare also joined the rally, closing 25.54% higher at 60,700 KRW on a mix of favorable US policy updates and expectations for its anti-aging hair loss tech. The American Medical Association (AMA) recently updated its Current Procedural Terminology (CPT) Category III codes, officially bringing the entire cycle of regenerative medicine—including custom 3D digital models and autologous tissue harvesting—into the formal medical billing system.This policy shift gives legal and billing backing to ROKIT Healthcare's core workflow, which combines AI image analysis, 3D bioprinting, and custom scaffold transplants for skin and cartilage regeneration. Previously, ROKIT's addressable market in the US was limited to roughly 1.5 million diabetic foot ulcer (DFU) patients. Under the new codes, Medicare and private insurance coverage can expand to include skin cancer reconstruction and severe chronic wounds, ballooning the company's Serviceable Obtainable Market (SOM) eightfold to 11.95 million patients. In response, the firm is investing 15 billion KRW this year in R&D and clinical expansion, while recruiting Dr. Nathan Lee as Chief Technology Officer (CTO) to accelerate commercialization.However, the company's other major claim—a natural substance-based technology that reportedly achieves "complete hair regrowth within 4 weeks"—is drawing comparisons to past bio sector hype. ROKIT has heavily marketed the tech as an epigenetic breakthrough that reverses the microenvironment of aging hair follicles. Yet, investigations show that the core technology is only in the provisional patent filing stage—a tool used to claim a priority date rather than a secured patent—and the specific compounds and mechanisms remain completely hidden. Distributing press releases claiming "complete hair regrowth" based solely on limited animal data, alongside contradictory statements from the company labeling the study as both a non-medical human application test and a Phase 1 clinical trial for a new drug, poses significant compliance risks. This friction comes at a time when the Financial Supervisory Service is tightening oversight on disclosure practices across the bio sector.A representative for ROKIT Healthcare focused on the regulatory progress, stating, "The change in US policy confirms that organ regeneration workflows merging AI and 3D bioprinting are being recognized as standard medical procedures in the US. We will execute our commercialization roadmap to capture the multibillion-dollar US market."
Copyright ⓒ 이데일리 무단 전재 및 재배포 금지
본 콘텐츠는 뉴스픽 파트너스에서 공유된 콘텐츠입니다.
다음 내용이 궁금하다면?
광고 보고 계속 읽기
원치 않을 경우 뒤로가기를 눌러주세요
